Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Neuron-Specific Expression of Zinc-Finger Repressors Mediate Widespread Prion Reduction in the Brain for the Potential Treatment of Prion Disease

Download PDF